Pharmacokinetics of cefpimizole in normal humans after single- and multiple-dose intravenous infusions
- PMID: 6524897
- PMCID: PMC180027
- DOI: 10.1128/AAC.26.6.802
Pharmacokinetics of cefpimizole in normal humans after single- and multiple-dose intravenous infusions
Abstract
The pharmacokinetics of cefpimizole (free acid equivalents of cefpimizole sodium), a broad-spectrum cephalosporin antibiotic, were determined after single- and multiple-dose 20-min intravenous infusions of 1, 2, and 4 g. The kinetics of single-dose administration of cefpimizole correspond to a two-compartment model with an average apparent volume of distribution of 20.0 +/- 3.5 liters, a distribution rate constant of 2.24 +/- 1.00 h-1, and a terminal rate constant of 0.358 +/- 0.036 h-1 (half-life, 1.9 h). The total body clearance was 118.6 +/- 20.2 ml/min. The primary route of elimination for cefpimizole was the renal route, with approximately 80% of the administered dose excreted as the parent compound. The elimination rate constant, as calculated from urinary excretion data, was 0.339 +/- 0.043 h-1, which is in close agreement with the terminal rate constant for plasma. Renal clearance of cefpimizole was 96.2 +/- 17.3 ml/min. Dose proportionality over the three dose levels was obtained from area under the plasma curve and cumulative urinary excretion data. The results of the multiple-dose study indicated that no apparent change in the distribution or elimination kinetics of cefpimizole occurred after the administration of 1-, 2-, and 4-g doses for 7 days, three times a day. The kinetics from the multiple-dose study were in close agreement with those from the single-dose study. No accumulation of cefpimizole occurred, and nondetectable levels was observed 24 h after administration of the last dose. Peaks that could be attributed to metabolites of cefpimizole were not observed during high-pressure liquid chromatographic analysis of either plasma or urine specimens.
Similar articles
-
Pharmacokinetics and dose proportionality of cefpimizole in normal humans after intramuscular administration.Antimicrob Agents Chemother. 1986 Feb;29(2):271-7. doi: 10.1128/AAC.29.2.271. Antimicrob Agents Chemother. 1986. PMID: 3717932 Free PMC article.
-
Tolerance and disposition of cefpimizole in normal human volunteers after intramuscular administration.Antimicrob Agents Chemother. 1987 Nov;31(11):1706-10. doi: 10.1128/AAC.31.11.1706. Antimicrob Agents Chemother. 1987. PMID: 3435119 Free PMC article. Clinical Trial.
-
Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora.Antimicrob Agents Chemother. 1983 Sep;24(3):333-8. doi: 10.1128/AAC.24.3.333. Antimicrob Agents Chemother. 1983. PMID: 6357074 Free PMC article.
-
Single- and multiple-dose pharmacokinetics of intravenous cefpirome (HR810) to healthy volunteers.J Clin Pharmacol. 1992 Mar;32(3):256-66. doi: 10.1002/j.1552-4604.1992.tb03834.x. J Clin Pharmacol. 1992. PMID: 1564130 Review.
-
A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum beta-lactam antibiotic.Ther Drug Monit. 1981;3(2):121-8. doi: 10.1097/00007691-198102000-00002. Ther Drug Monit. 1981. PMID: 6455787 Review.
Cited by
-
Pharmacokinetics and dose proportionality of cefpimizole in normal humans after intramuscular administration.Antimicrob Agents Chemother. 1986 Feb;29(2):271-7. doi: 10.1128/AAC.29.2.271. Antimicrob Agents Chemother. 1986. PMID: 3717932 Free PMC article.
-
Tolerance and disposition of cefpimizole in normal human volunteers after intramuscular administration.Antimicrob Agents Chemother. 1987 Nov;31(11):1706-10. doi: 10.1128/AAC.31.11.1706. Antimicrob Agents Chemother. 1987. PMID: 3435119 Free PMC article. Clinical Trial.
-
In vitro comparative antimicrobial activity of cefpimizole against clinical isolates from five medical centers.Antimicrob Agents Chemother. 1985 Jun;27(6):982-4. doi: 10.1128/AAC.27.6.982. Antimicrob Agents Chemother. 1985. PMID: 4026275 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources